Sana Biotechnology, Inc. — All Filings
361 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
144/A
3
3/A
4
4/A
424B4
424B5
8-A12B
8-K
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
FWP
POS AM
POS EX
POSASR
S-1
S-1/A
S-1MEF
S-3ASR
S-8
SC 13G
SC 13G/A
SCHEDULE 13G
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| DEF 14A | DEF 14A | 0001193125-25-094656 | Apr 25, 2025 | Jun 5, 2025 |
| DEFA14A | DEFA14A | 0001193125-25-094670 | Apr 25, 2025 | — |
| ARS | ARS | 0001193125-25-094675 | Apr 25, 2025 | Dec 31, 2024 |
| SCHEDULE 13G/A | — | 0002052113-25-001704 | Apr 25, 2025 | — |
| 4 | PRIMARY DOCUMENT | 0001562180-25-003066 | Apr 8, 2025 | Apr 7, 2025 |
| EFFECT | — | 9999999995-25-000728 | Mar 21, 2025 | — |
| 8-K | 8-K | 0000950170-25-040241 | Mar 17, 2025 | — |
| 10-K | 10-K | 0000950170-25-040254 | Mar 17, 2025 | Dec 31, 2024 |
| POS AM | POS AM | 0001193125-25-055657 | Mar 17, 2025 | — |
| POSASR | POSASR | 0001193125-25-054813 | Mar 14, 2025 | — |
| 4 | PRIMARY DOCUMENT | 0001562180-25-002274 | Mar 10, 2025 | Mar 6, 2025 |
| 4 | PRIMARY DOCUMENT | 0001562180-25-002271 | Mar 10, 2025 | Mar 6, 2025 |
| 4 | PRIMARY DOCUMENT | 0001562180-25-002273 | Mar 10, 2025 | Mar 6, 2025 |
| 4 | PRIMARY DOCUMENT | 0001562180-25-001888 | Mar 3, 2025 | Mar 2, 2025 |
| 144 | — | 0001950047-25-000950 | Feb 18, 2025 | — |
| SCHEDULE 13G/A | — | 0000932471-25-000210 | Jan 31, 2025 | — |
| 144 | — | 0001950047-25-000291 | Jan 16, 2025 | — |
| 8-K | 8-K | 0001193125-25-005047 | Jan 13, 2025 | — |
| 4 | 4 | 0000950170-25-004052 | Jan 10, 2025 | Jan 8, 2025 |
| 4 | PRIMARY DOCUMENT | 0001562180-25-000238 | Jan 7, 2025 | Jan 6, 2025 |
| 4 | PRIMARY DOCUMENT | 0001562180-25-000105 | Jan 3, 2025 | Jan 2, 2025 |
| 144 | — | 0001950047-24-009879 | Dec 16, 2024 | — |
| 144 | — | 0001963745-24-000051 | Nov 26, 2024 | — |
| 144 | — | 0001950047-24-009115 | Nov 25, 2024 | — |
| 3/A | 3/A | 0000950170-24-129613 | Nov 21, 2024 | Apr 1, 2024 |
| SC 13G/A | SC 13G/A | 0001104659-24-117983 | Nov 14, 2024 | — |
| SC 13G/A | ARCH VENTURE FUND IX, L.P. - SANA BIOTECHNOLOGY -- SCH 13G/A(#3) | 0001072613-24-000883 | Nov 14, 2024 | — |
| SC 13G/A | — | 0000932471-24-001160 | Nov 12, 2024 | — |
| SC 13G/A | — | 0000315066-24-002853 | Nov 12, 2024 | — |
| SC 13G | — | 0002012383-24-003529 | Nov 8, 2024 | — |
| 8-K | 8-K | 0000950170-24-123727 | Nov 8, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-123730 | Nov 8, 2024 | Sep 30, 2024 |
| SC 13G/A | — | 0000932471-24-000757 | Nov 4, 2024 | — |
| SC 13G | — | 0002012383-24-001603 | Oct 22, 2024 | — |
| 144 | — | 0001950047-24-007830 | Oct 21, 2024 | — |
| 3 | PRIMARY DOCUMENT | 0001562180-24-007331 | Oct 15, 2024 | Oct 4, 2024 |
| 4 | PRIMARY DOCUMENT | 0001562180-24-007283 | Oct 9, 2024 | Oct 7, 2024 |
| 8-K | 8-K | 0000950170-24-113524 | Oct 8, 2024 | Oct 4, 2024 |
| 4 | PRIMARY DOCUMENT | 0001562180-24-006954 | Sep 26, 2024 | Sep 24, 2024 |
| 144 | — | 0001950047-24-007386 | Sep 25, 2024 | — |
| 144 | — | 0001950047-24-007370 | Sep 24, 2024 | — |
| 8-K | 8-K | 0001193125-24-218049 | Sep 12, 2024 | Sep 6, 2024 |
| 8-K | 8-K | 0000950170-24-093976 | Aug 8, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-094052 | Aug 8, 2024 | Jun 30, 2024 |
| 4/A | PRIMARY DOCUMENT | 0001562180-24-005721 | Jul 15, 2024 | Jun 6, 2024 |
| 4/A | PRIMARY DOCUMENT | 0001562180-24-005722 | Jul 15, 2024 | Jun 6, 2024 |
| 4/A | PRIMARY DOCUMENT | 0001562180-24-005723 | Jul 15, 2024 | Jun 6, 2024 |
| 4/A | PRIMARY DOCUMENT | 0001562180-24-005724 | Jul 15, 2024 | Jun 6, 2024 |
| 4/A | PRIMARY DOCUMENT | 0001562180-24-005719 | Jul 15, 2024 | Jun 6, 2024 |
| 4/A | PRIMARY DOCUMENT | 0001562180-24-005715 | Jul 15, 2024 | Jun 6, 2024 |